secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0000914475-25-000180
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M
--------------------------------------------------------------------------------

- GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.
- INGREZZA net sales $686.6M (+12% YoY) driven by record quarterly new and total prescriptions.
- CRENESSITY launch generated $98.1M net sales with 540 new patient enrollment start forms.
- FY2025 INGREZZA guidance reaffirmed at $2.50-2.55B; GAAP R&D $1.00-1.02B, SG&A $1.14-1.16B.
- Initiated second Phase 3 trial for direclidine (schizophrenia); osavampator Phase 3 in MDD enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/0000914475-25-000180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/nbix-20251028.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer